Bind Appoints CSO
This article was originally published in Scrip
Bind Therapeutics, Inc. has appointed Jonathan Yingling chief scientific officer (CSO). Before joining Bind, Yingling was vice president of oncology discovery and translation research at Bristol-Myers Squibb. His pharmaceutical career began in 2000 as a senior biologist in oncology at Eli Lilly & Co., where he spent 13 years in various positions including CSO of angiogenesis and tumor microenvironment biology, vice president of oncology research and vice president of translation science and technology.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.